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SPONTANEOUS AND INDUCED 
GENETIC MUTATIONS OF THE POMC 
SYSTEM 
James L. Smart and Malcolm J. Low 
Vollum Institute, Oregon Health Sciences University, Portland OR 97201, U.S.A. 
INTRODUCTION 
Two decades ago a senes of biochemical experiments conclusively 
demonstrated that adrenocorticotropin (ACTH) and f3-lipotropin (f3LPH) 
peptides were stoichiometrically generated from a common precursor (1). 
This result was heralded by one of the landmark studies in the nascent field 
of eukaryotic cloning, the sequencing of a pituitary eDNA whose deduced 
amino acids encoded both peptides separated by a pair of basic amino acids 
(Lys-Arg) (2). Subsequent work demonstrated that the proopiomelanocortin 
(POMC) prohormone is posttranslationally processed into several 
biologically active peptides in addition to ACTH and f3LPH. Among these 
are the melanocortin melanocyte-stimulating hormone ( aMSH) and the 
potent opioid f3-endorphin (f3END). The mechanism of POMC processing 
became a paradigm in cellular biology for the elucidation of vesicular 
trafficking and enzymatic cleavage of secreted peptides from prohormone 
precursors. A renaissance of scientific interest in POMC has occurred in 
more recent years with the cloning of a gene family of melanocortin 
receptors and the demonstration of central melanocortin effects on energy 
homeostasis. This chapter will review the ongoing role that spontaneous and 
induced (transgenic and "knockout") mutant mouse models have played in 
the analysis of POMC gene regulation and biological function. 
Biosynthesis and Post-translational Processing of POMC 
Several comprehensive reviews of POMC processing have been published (3, 
4). This section will serve only to introduce major points relevant to the mouse 
models under consideration and is summarized in Table 1. The principal sites 
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of POMC expression are corticotrophs and melanotrophs of the pituitary gland 
and subsets of neurons in the arcuate nucleus (ARC) of the hypothalamus and 
in the caudal nucleus of the solitary tract (NTS) within the dorsal vagal 
complex of the medulla (5-7). Endoproteolytic cleavage of POMC by a 
prohormone convertase (PC1/PC3) in corticotrophs yields ACTH, l3LPH, and 
an NHrterminal peptide (Pro-yMSH). The latter peptide and/or further 
proteolytic derivatives have been postulated to mediate paracrine growth and 
secretory effects within the anterior lobe and to stimulate mitogenesis in the 
adrenal cortex (8, 9). A small proportion of !3LPH is cleaved to yield yLPH 
and (3ENDI-31. However, in melanotrophs of the intermediate lobe virtually 
all l3LPH is cleaved by PC2 to yLPH and (3ENDI-31. The latter peptide is 
acetylated on its NH2-tyrosine and truncated by the action of a 
carboxypeptidase to yield Ac-13ENDI-27 and Ac-13ENDI-26. The acetylated 
opioid peptides have a greatly reduced affinity for ll and 8 opioid receptors 
and their biological function has not been satisfactorily determined. aMSH is 
acetylated on its NH2-serine and amidated on its COOH-terminal to yield a 
fully bioactive peptide. BMSH is an additional endoproteolytic product of 
human yLPH but is not generated from rodent yLPH because it lacks the 
necessary consensus amino acid sequence for cleavage by a PC. 
Endoproteolytic processing of POMC in ARC neurons closely mirrors the 
processing in melanotrophs. The neuronal aMSH is fully amidated, but there 
is minimal NH2.acetylation of peptides or COOH-terminal shortening of 
13ENDI-31. yMSH and/or y3MSH are processed from the NHrPOMC domain 
in ARC. 
Table 1. POMC Peptides and their Cognate G-Protein Coupled Receptors "'P�P'ii�-"·��-"·�··· .. ·--ceil�Tz;rig��-Rt;�;pi��-�----r;.g;t;i"t��----F��ti� --·--· -· 
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Pro-yMSH Corticotrophs MC3-R, ? Pituitary cells Paracrine action 
Ac-aMSH-NH2 Melanotrophs MCI-R Melanocytes Pigmentation 
Ac-�ENDI-27 Melanotrophs f.t,O t Kct Peripheral sites Modulation? 
DesAc-aMSH Pituitary MC5R Exocrine glands Secretion 
yMSH, y3MSH ARC neurons MC3-R Limbic system Homeostasis 
DesAc-aMSH- ARC neurons MC4-R Hypothalamus Homeostasis 
NH2,ACTH 
�END!-31 ARC neurons ll = 8 > K Diffuse CNS Analgesia, reward 
- ·--·--· -��. =..,...,_.,.. ........,. ..., ..,�. �-�""""""" """""' ""'-· ----· --· --·-· ----
Five distinct members of a G-protein coupled, melanocortin receptor gene 
family have been cloned (reviewed in (I 0)). MC 1-R is expressed on 
melanocytes within the skin and its activation by Ac-aMSH-NH2 leads to 
increased membrane adenylyl cyclase activity by interaction with Gsa and 
subsequently greater production of the brown-black eumelanin pigment and 
less of the yellow-red phaeomelanin. MC2-R is the classical ACTH receptor 
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expressed on zona glomerulosa and fasiculata cells of the adrenal cortex and 
it has very low affinity for the various melanocortin peptides other than 
ACTH and ACTHI-24 (11). Two additional members of the gene family, 
MC3-R and MC4-R are expressed exclusively in the CNS in partially 
overlapping but distinct neuroanatomical areas with particularly high 
abundance in the hypothalamus and limbic system (12, 13). The MC3-R has 
the highest affinity for yMSH, although it is also activated by other 
melanocortins, while the MC4-R is activated most selectively by aMSH and 
ACTH. Together these receptor subtypes mediate most of the described 
melanocortin effects on appetite, metabolism, thermoregulation, autonomic 
outflow, and behavior. The MC5-R is the most ubiquitously expressed of the 
melanocortin receptors and its best-documented function is the stimulation of 
exocrine function including the sebaceous, preputial, Harderian, and lacrimal 
glands (14). 
Three opioid receptor genes have been cloned corresponding to the f.!, &, and 
K receptors originally defined by their pharmacological profiles (15, 16). 
PENDl-31 has highest and nearly equivalent affinity to both f.! and & 
receptors (17). However, each of these subtypes has significant affinity for 
other opioid peptides derived from the proenkephalin and prodynorphin 
precursors. 
POMC Peptides and Energy Homeostasis 
Classical ablation or disconnection experiments utilizing electrolytic and 
chemically generated lesions or knife cuts of the mammalian brain revealed a 
number of discrete areas within the medial-basal hypothalamus to be nodal­
points in the regulation of energy homeostasis (reviewed in (18)). One 
principal area characterized in this fashion is the ARC located at the base of 
the hypothalamus and adjacent to the third ventricle. The ARC extends 
rostrocaudally from the posterior border of the optic chiasm to the anterior 
border of the mammillary nuclei. A subset of hypothalamic neurons 
distributed throughout the ARC express the POMC gene. These POMC 
neurons densely innervate other brain areas implicated in energy 
homeostasis, motivated behavior, and autonomic control including the 
vetromedial nucleus of the hypothalamus (VMN), dorsomedial nucleus of the 
hypothalamus (DMH), paraventricular nucleus of the hypothalamus (PVN), 
lateral hypothalamic area (LH), ventral tegmental area (VT A), para brachial 
nucleus, and NTS. 
The lesion studies showed that disruption of the mammalian ARC correlated 
with an obese phenotype and led to the concept that this area of the 
hypothalamus contained a satiety center. Later efforts focused on 
determining the specific neuronal phenotype in the ARC that was involved in 
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the regulation of energy homeostasis. An early indication of the importance 
of POMC peptides was the detection of MSH binding by autoradiography in 
the VMN, another hypothalamic nucleus involved in regulating appetite and 
feeding (19). In addition, central or peripheral injections of melanocortin 
peptides were shown to affect food intake. Melanocortins appear to have 
dual roles in energy balance, depending on the site of action. Administration 
of ACTH and Ac-aMSH directly into adipose tissue increases lipolysis 
whereas intramuscular injection of DesAc-a.MSH increases food intake. 
Furthermore, peripheral DesAc-a-MSH inhibits pituitary production of ACTH 
and Ac-a.MSH, which may lead to increased lipogenesis (20). MSH 
analogues administered i.c.v. or injected stereotaxically directly into the PVN 
of rodents have potent anorexigenic effects and stimulate metabolic rate (21). 
Exogenous opiates and endogenous opioid peptides have also been shown to 
affect food consumption and food preference, suggesting a role for POMC­
derived f3-endorphin, in addition to the melanocortin peptides, as a modulator 
of energy homeostasis (22-24). The physiology of this complex 
neuroendocrine system is virtually impossible to replicate in in vitro models. 
Thus, transgenic mice and mice with naturally occurring mutants or targeted 
genetic alterations have been extremely informative tools for the analysis of 
POMC peptides and their receptors in the control of food intake, energy 
partitioning, and body weight. 
One of the first mutant mouse models of obesity to be studied was the lethal 
yellow (Aria) mouse (25). The mutation arose spontaneously in the C57BL/6 
inbred strain and is associated with a striking yellow coat color and the 
development of obesity and hyperphagia. Genetically, the mutation was 
shown to be dominant to the extension (E) locus, later identified as the gene 
encoding the MC-1 receptor (26). Cloning of the agouti gene revealed that it 
encodes a secreted protein characterized by multiple pairs of intrachain 
disulfide bonds in its C-terminal domain. Agouti has high affinity binding for 
the MC1-R, antagonizes receptor activation by MSH (27), and is normally 
transiently expressed only in the hair follicles accounting for the yellow 
banding of individual black hairs in the fur of many mammals. The mutant 
Ar allele results from a 120 kb genomic deletion and juxtaposition of the 
agouti coding sequences to the Raly gene locus and subsequent ubiquitous 
expression of agouti protein from the Raly promoter (25). These observations 
led to the agouti-obesity hypothesis, which states that agouti protein 
expressed within the brain antagonizes the action of central MSH to a neural 
MC receptor involved in regulation of energy balance. Some of the 
experimental models reviewed in this chapter provide essential data in 
support of this hypothesis, which has been further validated by the discovery 
and cloning of an agouti homologue, agouti gene-related protein (AGRP). 
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AGRP is expressed in the nervous system and functions as an antagonist of 
central MC receptors (28). 
Genetic linkage studies and quantitative trait loci analyses have strongly 
implicated the POMC gene locus as an important determinant of weight 
homeostasis in humans of many different ethnic populations, although 
specific alleles associated with obesity have not yet been demonstrated (29, 
30). Because no mutations within the coding region of the POMC gene that 
alter peptide activity have been identified in these populations, a current 
hypothesis is that mutations in regulatory regions of the gene decrease the 
level of POMC expression in the brain. However, a small number of 
children from cosanguineous parents have been found to have null mutations 
in the POMC gene resulting in the absence of detectable circulating ACTH 
(31). These children presented with a syndrome of red hair, adrenal 
insufficiency and severe, early-onset obesity. In addition, both dominant and 
recessive mutations in the MC4-R gene have been found in the human 
population, and MC4-R mutations have been proposed to play a role in as 
many as 5% of pediatric obesity cases (32, 33). 
POMC GENE REGULATION 
A standard method to characterize the cis DNA elements and transcription 
factors that control POMC gene transcription has been the expression of 
fusion genes, consisting of POMC promoter sequences and a reporter 
sequence, in transfected cell lines. The most commonly used cell line is 
AtT20, originally derived from a radiation-induced pituitary tumor (34). 
These cells have many characteristics of primary corticotrophs. Snrtall cell 
lung cancers often ectopically express POMC and cell lines derived from 
these tumors have also been used for the analysis of POMC gene expression 
(35). It is clear, however, that neither of these cell lines are adequate models 
for elucidation of the mechanisms governing neural-specific expression of 
the POMC gene. For this reason, our laboratory has focused on a transgenic 
mouse approach for the identification of cell-type specific regulatory 
elements in the POMC gene. 
Promoter Analysis in Transgenic Mice 
The Drouin laboratory was the first to report the generation of transgenic 
mice expressing a neomycin-resistance coding sequence (neo) from 770 
bases of the rat POMC promoter (36). Although the expression pattern in 
pituitary and regulation by adrenalectomy and dexamethasone were 
consistent with accurate cellular expression of the transgene, the low levels 
of transcript from the neo reporter prevented the direct demonstratation of 
corticotroph and melanotroph specific transcription. Our laboratory initially 
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approached this problem using an E. coli lacZ reporter gene encoding a­
galactosidase, which was useful for both the precise cellular identification of 
transgene expression and quantitation of transcriptional activity by an 
enzymatic assay utilizing a fluorigenic substrate. These studies demonstrated 
that 770 bases of the rat POMC promoter from nucleotide -706 in the 5' 
flanking sequences to +64 in the 5' untranslated region of exon 1 were 
sufficient to direct lacZ expression selectively to pituitary corticotrophs and 
melanotrophs (Figure 1, POMC-LacZ) (37). The ontogeny of transgene 
expression also closely approximated the time course of endogenous POMC 
gene expression in the two lobes of the pituitary gland. However, there was 
no detectable expression of the -706POMC-lacZ transgene in the brain 
suggesting that additional genomic sequences were necessary for neuronal 
transcription. 
Additional studies from our laboratory analyzed the rat POMC promoter in 
more detail to define the minimal elements essential for pituitary expression 
(38, 39). Accurate cell-specific colocalization was verified in all instances by 
double-label immunofluoresence histochemistry. Truncations of the rat 
POMC promoter to nucleotide -323 or -234 had minimal effects on both the 
ratio of expression-positive to total transgenic pedigrees and qualitative 
levels of reporter expression in the positively expressing lines. Further 
deletion of the 5' flanking sequences to nucleotide -160 abolished expression 
in the pituitary gland. Transfection studies in AtT20 cells had identified 
important regulatory elements in the core promoter region of the POMC 
gene. However, we demonstrated that the enhancerless promoter and TATA 
box from the HSV1 thymidine kinase gene were equivalent to the native 
POMC promoter sequences between nucleotides -34 and +64, in the context 
of upstream flanking sequences of POMC, to support pituitary cell-specific 
expression and normal upregulation by adrenalectomy. Based on these 
promoter truncation studies in transgenics and our data from DNAse I 
protection assays and gel-shift assays utilizing POMC oligonucleotide probes 
and fractionated nuclear proteins from AtT20 cells, we designed a series of 
more discrete mutations in the rat POMC promoter. This second generation 
of transgenic experiments identified two functionally important protein 
binding sites at nucleotide positions -262/-253 and -202/-193 of the POMC 
gene (39). At least one of these sites had to be intact to support detectable 
pituitary expression of the transgenes. In addition, the ubiquitous 
transcription factor SP1 appeared to play a supportive role in POMC 
transgene expression through its interaction with DNA sites at positions 
-201/-192 and -146/-136. 
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Fig 1. Restriction maps of the mouse POMC gene locus, transgene 
constructs utilized to map the location of tissue-specific regulatory elements, 
and targeted POMC alleles that either selectively prevent B-endorphin 
production or result in the absence of all POMC peptides. See text for details 
of the individual alleles. 
None of the transgene constructs that we studied selectively directed 
expression to only pituitary melanotrophs or corticotrophs, suggesting that 
both cell types share one or more essential components for POMC gene 
transcription. In common with most published transgenic promoter analyses, 
we observed a large quantitative and qualitative range of expression levels 
among independent pedigrees for each construct. It has been suggested that 
these mosaic patterns of gene expression are influenced by repressive effects 
of multiple-copy transgene integration in some cases ( 40). In general, basal 
expression of the transgenes appeared to be greater in individual 
melanotrophs than corticotrophs, regardless of the type of reporter molecule. 
The data from our transgenic promoter analyses revealed a number of 
inconsistencies with the mapping of functional POMC promoter elements by 
transfection studies in AtT20 cells. These differences may be due in part to 
1,,, 
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the more stringent requirement in transgenic mice for the definition of cell­
specific expression and the importance of chromatin remodeling during in 
vivo development. However, there is good agreement between both kinds of 
studies for the key importance of DNA elements between nucleotides -I60 
and -323 in the 5' flanking domain of the POMC gene. This region contains 
a site between -I73/ -I60 that appears to mediate the transcriptional activating 
effects of both corticotroph releasing hormone (CRH) and the cytokine 
leukemia inhibitory factor (LIF), although it is neither a binding site for 
CREB, AP-I or STAT proteins (4I). In contrast, the POMC TATA box, a 
putative AP-I binding site in exon I, and more distal sites in the POMC 5' 
flanking sequences that bind HLH proteins and confer a synergistic 
activation of POMC expression in AtT20 cells do not appear to be essential 
for pituitary cell-specific expression in the in vivo paradigm ( 42). 
Generation of Novel POMC Expressing Cell Lines 
Targeted cellular expression of oncogenes with tissue-specific promoters has 
led to new insights into the molecular basis of tumorigenesis. Several 
laboratories have used this technique to isolate novel differentiated cell lines 
(43-46). We used the rat POMC promoter elements to express two isoforms 
of the simian virus SV 40-Large T antigen in pituitary corticotrophs and 
melanotrophs. Wild-type SV 40Tag consistently induced tumors in the 
pituitary gland, as predicted, but also in the thymus gland with incomplete 
penetrance of the phenotype ( 4 7). However, the incidence of thymic tumors 
decreased and eventually disappeared after I5 generations of backcrossing to 
an outbred CD-I genetic background, suggesting that epistatic interactions 
with gene alleles from the original B6D2 genetic background were necessary 
for expression of the transgene in thymus. In contrast, the pituitary tumor 
phenotype remained stable after 27 generations of breeding (48). The 
variable latency to tumor development in these mice is consistent with the 
idea that stochastic secondary events likely occur in individual T -antigen 
expressing cells before they are transformed and lose their inhibitory growth 
controls. Other transgenic mice expressing the temperature-sensitive tsA58 
mutant form of SV40Tag from the same POMC promoter sequences only 
developed pituitary tumors after I year of age (our unpublished data). The 
longer latency was presumably due to the expression of minimal amounts of 
biologically stable tsA5 8-Tag at the partially permissive core body 
temperature of the mice. 
Although the POMC-Tag transgene is expressed in both pttmtary 
corticotrophs and melanotrophs, every pituitary tumor that has developed in 
the mice has been of melanotroph origin based on visual inspection and 
biochemical and molecular studies. The melanotroph tumor cells are fully 
transformed because they will produce secondary tumors after subcutaneous 
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passage in nude mice and will freely grow in suspension culture (47, 49). 
Unlike the strict dependence for IGF-II in the induction and progression of 
pancreatic islet J3-cell tumors from an insulin promoter-Tag transgene (50), 
we found no evidence for a critical role of the IGF system in the POMC-Tag 
induced pituitary tumors (51). Posttranslational processing of POMC in the 
primary tumors was indistinguishable from normal melanotrophs and was 
characterized by high proportions of NH2-acetylated and COOH-truncated 
forms of J3-endorphin and Ac-aMSH with virtually no ACTH (47). Even 
though the tumors expressed high levels of PC2, which is characteristic of 
melanotrophs, there was frequently a sufficient quantity of an ACTH-like 
peptide secreted from the neoplastic glands to induce adrenal cortical 
hyperplasia and elevated serum corticosterone. A syndrome of fatal 
melanotroph-dependent Cushing's disease was recently reported in mice with 
a null mutation in the gene encoding the neuroendocrine protein 7B2 (52) 
(see Chapter 8). 7B2 has been implicated in the activation of PC2, accounting 
for the lack of functional PC2 production and generation of ACTH instead of 
Ac-aMSH and CLIP in melanotrophs of the 7B2 null mice. However, it 
remains unexplained why ACTH is constitutively secreted from the 
intermediate lobe of these mice because a knockout of the PC2 gene results 
in similarly high ACTH production in melanotrophs without the unregulated 
secretion of the hormone (53). Therefore, 7B2 may have an additional 
function in vesicular trafficking or secretion. 
Two cell lines with distinct phenotypes were isolated from cultures of the 
mouse melanotroph tumors (54). miL39 cells are melanotrophs based on 
their expression of both POMC and the dopamine 02 receptor. They are 
small, bipolar cells and rapidly produce secondary tumors after 
transplantation into nude mice. In contrast, miL5 cells fail to express either 
POMC or detectable levels of SV40Tag. The exact origin of these latter cells 
is unknown but they are of interest because they secrete a prolactin­
regulating factor. The lack of concordance between this prolactin-regulating 
.·ctivity and POMC gene expression suggests that the activity is not due to a 
peptide product of POMC. More recently our laboratory has isolated another 
melanotroph-like cell line from a pituitary tumor induced by the 
tsA58SV40Tag (Chronwall et al, submitted). These cells express high levels 
of POMC mRNA and POMC prohormone but they have few secretory 
granules and limited posttranslational processing of POMC. Preliminary 
studies have demonstrated the expression of several G-protein coupled 
receptors including dopamine 02, CRH Rl, and GABAB that are normally 
expressed on melanotrophs. These receptors are functional and therefore this 
cell line may be useful for analyzing the biochemical cross-talk in signaling 
pathways that are unique to pituitary melanotrophs. 
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Targeting POMC Neurons In Vivo 
Because neither 770 or 4000 bp of the 5' flanking sequence from the rat 
POMC gene were sufficent to produce appropriate neuronal expression in 
transgenic mice (55), longer mouse genomic POMC clones were isolated 
from a cosmid library. Exon 3 was marked with an oligonucleotide sequence 
to distinguish transgenic mRNA from endogenous POMC mRNA and to 
enable the simultaneous quantitation of both mRNA species by an RNAse 
protection assay. A new series of transgenic mice was generated and analyses 
of mRNA expression in the mice clearly established the location of a putative 
neuron-specific enhancer within an 11 kb stretch of 5' flanking DNA 
sequences between -13 kb and -2 kb relative to the transcriptional start site 
(Figure 1, L\3'P27* and HAL*) (56). Transgene constructs containing these 
sequences have had a 100% penetrance of correctly targeted expression in 
neurons of both the ARC and NTS, consistent with the existence of a locus­
control type regulatory element within the POMC gene. There is also total 
concordance of pituitary expression with neural expression from the longer 
genomic constructs indicating that an overlapping subset of POMC 
regulatory elements and cognate transcription factors may be required for 
transcription in both cell types. The recent identification of a novel 
neuropeptide precursor gene, cocaine and amphetamine responsive-transcript 
(CART), as a cotransmitter in POMC arcuate neurons suggests that these two 
distinct genes may also share a subset of regulatory factors (57, 58). 
Ongoing functional analyses of the distal POMC genomic sequences 
combined with recent advances in the human and mouse genome projects 
should rapidly lead to the identification of the minimal DNA elements that 
are responsible for neural-specific expression. It will then be possible to 
compare these sequences with the corresponding regions of DNA amplified 
from obese subjects to test the hypothesis that mutations in POMC regulatory 
sites are the molecular basis for the genetic linkage established by QTL 
analyses (29). Ultimately, the functional significance of nucleotide 
differences identified by this type of horizontal genetic comparison can be 
tested in mice by targeted mutagenesis and analyses of POMC expression in 
hypothalamus, feeding behavior, and energy partitioning. 
Our characterization of neural-specific regulatory regions in the POMC gene 
provided a means to identify viable POMC neurons using a nondestructive, 
green fluorescent protein (enhanced-GFP) reporter (Cowley et al., 
submitted). Previously, the analysis of cellular events in POMC neurons has 
been limited because of their small number and sparse distribution. Bright 
green fluorescence was readily identified in the basal hypothalamus and in 
the NTS of transgenic mice expressing a POMC-EGFP construct (Figure 1). 
Double-labeling immunofluorescence with a B-endorphin antisera revealed 
>99% cellular colocalization of EGFP and endogenous POMC peptide 
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expression within the ARC. The developmental onset of EGFP expression in 
both hypothalamic and pituitary cells also matched the ontogeny of native 
POMC. 
POMC neurons are an important site of leptin receptor expression in the 
hypothalamus (59). The adipocyte derived hormone leptin regulates long­
term aspects of energy homeostasis by signaling the levels of fat mass to the 
brain. Leptin also has acute actions to stimulate cjos and Socs3 expression 
in POMC neurons and can cause the release of B-endorphin from 
hypothalamic fragments in vitro (60). Therefore, the POMC-EGFP 
transgenic mice will be a useful tool to test the hypothesis that leptin directly 
activates POMC neurons. Preliminary electrophysiological experiments in 
hypothalamic slices suggest that leptin has both pre- and postsynaptic actions 
on POMC neurons to increase the frequency of spontaneous action 
potentials. Additional studies using this transgenic mouse line will decipher 
the role of other peptidergic modulators, cytokines, and amino acid 
neurotransmitters on POMC neuronal activity. EGFP-labeled POMC neurons 
can also be used for investigation of neuronal migration during development 
and as a unique source of mRNA for differential gene expression analyses. 
Similar techniques to identify rare neuronal populations in vivo are 
increasingly being used by other laboratories. A prime example is the 
identification of GnRH neurons as described in Chapter 3 of this volume and 
by other investigators (61). 
In principle, the neural-specific regulatory sequences of the POMC gene can 
be used to target expression of foreign or mutated proteins to POMC neurons 
to investigate intracellular signaling pathways in situ. For example, leptin 
resistance may be associated with alterations in the capacity for leptin 
signaling through either JAK/Stat or MAPK cascades. Individual molecular 
steps in these pathways could be perturbed by the use of dominant-negative 
factors or expression of natural inhibitor proteins. Finally, targeted oncogene 
expression to POMC neurons may lead to the isolation of a differentiated 
POMC neuronal cell line, which would greatly facilitate molecular studies of 
POMC gene regulation and the membrane properties of the neurons 
themselves. 
MUTATIONAL ANALYSIS OF POMC FUNCTION 
TARGETED MUTAGENESIS OF THE POMC GENE 
13-endorphin-Deficient Mice 
B-endorphin-deficient mice were generated by the introduction of a point 
mutation into the POMC gene by homologous recombination in embryonic 
186 POMC System Transgenic Models 
stem cells (62). The nucleotide insertion at the amino-terminal tyrosine of 
BEND introduced a premature translational stop-codon into exon 3 (Figure 1, 
construct POMCX*4). Homozygous mice carrying this mutated allele 
express normal levels of POMC mRNA in pituitary and ARC. The mRNA 
encodes a COOH-truncated POMC prohormone that is processed normally to 
ACTH and other melanocortin peptides (63). The mice have no detectable 
immunoreactive BEND and have been used to infer the normal physiological 
function of this specific endogenous opioid peptide. Basal activity of the 
hypothalamic-pituitary-adrenal axis is normal and the PEND-deficient mice 
have normal corticosterone responses to a variety of stressors. PEND­
deficient mice exhibit unaltered nociceptive thresholds and unaltered 
antinociceptive responses to i.p. morphine administration. However, PEND­
deficient mice fail to exhibit endogenous opioid-mediated stress-induced 
antinociception and have increased levels of nonopioid (naloxone insensitive) 
stress-induced antinociception (63). Complimentary studies in enkephalin­
deficient mice have demonstrated that they retain endogenous opioid stress­
induced antinociception (64). Taken together, these data provide convincing 
genetic evidence that BEND derived from the POMC prohormone, and not 
the more abundant enkephalin peptides, is the natural opioid mediating 
stress-induced antinociception. The most likely relevant neuroanatomical 
substrate is the projection of ARC POMC neurons to the central 
periaqueductal gray known to modulate descending antinociceptive pathways 
to the brainstem and spinal cord. 
More recent studies have demonstrated that the BEND-deficient mice have 
altered antinociceptive responses to morphine administered i.c.v. or i.t. The 
mutant mice are more sensitive to the antinociceptive action of morphine 
injected centrally into the lateral ventricle but less sensitive to morphine 
injected into the spinal compartment, compared to wild-type control mice 
(65). The f..l-Specific agonist DAMGO produced qualitatively identical results 
indicating the importance of the fl opioid receptor in the phenotype. Total 
binding sites for the fl, 8, and K receptors, assessed by quantitative 
autoradiography, were normal in the BEND-deficient mice suggesting that 
subtle alterations in fl receptor signaling may be the mechanism for the 
opposing alterations in central and spinal sensitivity to morphine. An 
electrophysiological study demonstrated a normal dose-response to DAMGO 
for the induction of an inwardly rectifying K+ current (GIRK) in mediobasal 
hypothalamic neurons of the mutant mice ( 66) consistent with the suggestion 
that fl receptor number, affinity, and coupling to G proteins are not altered by 
the complete absence of BEND. 
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Opioids, including PEND, have generally been shown to increase food intake 
in pharmacological studies (67). Paradoxically, p-endorphin deficient mice 
exhibit a sexually dimorphic obesity phenotype due to increased white fat 
mass in males (Appleyard et al, submitted). The male mice are slightly 
hyperphagic and have a normal basal metabolic rate. It is not yet clear if 
POMC derived melanocortins and 13END are involved in a parallel, 
redundant anorexigenic pathway within the hypothalamus or if PEND 
additionally plays a role in an opioid reward pathway that is activated by 
feeding. 
Null Mutation of the POMC Gene 
Mice that are deficient in all POMC peptides (POMC Null) were generated 
by the Hochgeschwender laboratory by homologous recombination of a 
POMC allele containing a deletion of exon 3 (Figure 1, POMC Null). The 
mice develop hyperphagia and obesity similar to that seen in the lethal 
yellow (Aria) mice and MC4-R deficient mice (68). In contrast to the other 
obesity models, POMC Null mice have no detectable levels of circulating 
corticosterone or epinephrine and their adrenal glands are one-third the size 
of wildtype littermates. The adrenal deficiencies in these mice strengthen the 
hypothesis that normal POMC expression is needed for complete adrenal 
maturation, although the role of NH2-terminal peptides in addition to ACTH 
remains an open question that can now be approached experimentally in vivo. 
A partial perinatal lethality occurs in litters produced from heterozygous 
breeder pairs leading to significantly decreased numbers of homozygous 
POMC Null offspring compared to Mendelian predictions. Homozygous 
POMC Null adults are fertile and females carry their litters to term but all 
pups die in the immediate perinatal period (our unpublished data). The 
mechanism for this pattern of perinatal lethality from both heterozygous and 
homozygous POMC Null female mice has not yet been explained, but may 
result from the combined lack of glucocorticoids and epinephrine in the 
POMC Null pups. 
In principle, the absence of all POMC peptides should recapitulate the sum of 
phenotypes observed in mice deficient in the various receptor subtypes for 
the peptides. Although not all the characteristics of the various receptor­
deficient mice have been investigated, some of the predicted phenotypes are 
absent in the POMC Null mice. In particular, POMC Null mice do not 
exhibit the hair pigmentation that would be expected based on the 
phenotypes of Aria yellow and null MC1-R mutants (see discussion in the 
following section). The original POMC Null mice bred on an agouti (AlA) 
129 genetic background had patchy alterations in their coat color, but were 
clearly not a uniform yellow (68). We have crossed the POMC Null allele 
onto the C57BL/6 (ala) genetic background and observed an unaltered black 
.: I 
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coat color in the mutant mice despite the absence of MSH, the only known 
natural agonist for the MCI-R (unpublished data). In sum, POMC deficient 
mice will be invaluable in deciphering the physiological roles of individual 
POMC peptides in the neuroendocrine and immune systems by transgenic 
strategies designed to rescue the expression of subsets of POMC products to 
either the pituitary and/or neural compartments. 
MELANOCORTIN AND OPIOID RECEPTOR GENE MUTATIONS 
Hypomorphic and Constitutively Active MCl-R Gene Alleles 
Classical genetic studies indicated that two independent loci, extension (E) 
and agouti (A), primarily controlled the ratio of eumelanin and phaeomelanin 
in melanocytes, and hence the color of individual hairs. The extension locus 
is cell-autonomous and approximately a decade ago was demonstrated to 
encode the MCR-1 or MSH receptor (26). Numerous naturally occuring 
mutations at the extension locus have been characterized genetically because 
of the relative ease in tracing the mutant alleles during backcrosses and 
intercrosses by observation of coat color. Recessive mutations of the mouse 
extension locus (e) result in a yellow coat color due to low levels of 
tyrosinase activity in melanocytes and a high phaeomelanin/eumelanin 
pigment ratio. The e allele encodes a nonfunctional MCR-1 resulting from a 
frameshift mutation and premature translational stop codon between the 
fourth and fifth transmembrane domains. Dominant mutations of the mouse 
E locus result in black coat color and are epistatic to agouti. The sombre (E') 
allele encodes a MCI-R containing a single activating point mutation. This 
MCI-R is constitutively active in the absence of MSH and therefore not 
antagonized by agouti protein, accounting for the genetic epistasis. These 
original data and the analyses of other mutant E alleles have been the basis of 
structure-function models to explain receptor activation by agonist ligand 
binding. Interestingly, identical mutations introduced into the other highly 
homologous MCR subtypes have generally not resulted in receptor activation 
emphasizing the important functional differences among these related G­
protein coupled receptors and the danger of over extrapolating data 
concerning ligand interactions from one receptor subtype to another. 
Null Mutation of the MC4-R Gene 
Targeted deletion of the MC4-R has shown it to play an important role in 
energy homeostasis. MC4-R is the predominant melanocortin receptor in the 
brain and genetically engineered mice homozygous for a null MC4-R allele 
an� obese, hyperphagic, and exhibit increased longitudinal growth ( 69), all 
features shared with the Aria yellow mouse. These data and the inability of 
the potent MSH analogue MTII to decrease food intake in MC4-R knockout 
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mice (70) indicate that the MC4-R is essential for the anorectic effects of 
central melanocortins. 
Null Mutation of the MC5-R Gene 
Transgenic mice deficient in the MC5-R do not exhibit any phenotypes that 
are directly associated with weight regulation or feeding but they do exhibit 
thermoregulatory defects and fail to repel water from their coat. These 
phenotypes were shown to be a result of reduced production and secretion of 
lipids from sebaceous glands in MC5-R deficient mice (14). Additionally, the 
mice exhibited decreased production and attenuated stress-induced synthesis 
of porphyrins by the Harderian glands and decreased protein secretion from 
lacrimal glands. All of these exocrine glands, including the preputial gland, 
are normally sites of high MC5-R expression. The results suggest the 
existence of a hypothalamic-pituitary-exocrine axis that potentially regulates 
pheromone production from exocrine glands in coordination with the 
behavioral arousal state of the mouse. 
Null Mutations of the MC3-R Gene 
Null mutations of the POMC (68) and MC4-R (69) genes, and transgenic 
overexpression or misexpression of the MC4-R antagonists agouti and AGRP 
(28, 71) all produce phenotypes that can be attributed to diminshed MC4-R 
signaling. Although these genetic models have provided great insight into the 
role of POMC and MC4-R in energy homeostasis, little specific information 
can be extracted regarding a contributory role of MC3-R signaling. The 
MC3-R, like the MC4-R, is expressed in the CNS but in a more restricted 
distribution including ARC and VMN. Recently, two groups independently 
published reports of knockout mice lacking the MC3-R (72, 73). MC3-R 
deficient mice exhibit nearly normal growth curves and body weight, but 
carcass analyses reveal a significant increase in white adipose mass. 
Additionally, MC3-R deficient mice are more susceptible than controls to 
developing obesity on a high fat diet. In contrast to the obesity phenotype 
exhibited in MC4-R deficient mice, which can mostly be explained by 
alterations in feeding behavior, the MC3-R deficient mice apparently have a 
predominant metabolic defect involving energy partitioning. They have 
higher feed efficiency and decreased lean mass. Mice lacking both the MC3-
R and MC4-R gain more weight than single MC4-R knockouts (73). 
Additional studies are needed to define the specific neural circuits 
responsible for the divergent actions of melanocortin peptides, MC3-R, and 
MC4-R on the regulation of food intake versus metabolic rate and energy 
expenditure. 
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Null Mutations of the Opioid Receptor Genes 
Each of the three genes encoding the classical opioid receptor subtypes has 
been deleted by homologous recombination in mice (16). Surprisingly, there 
have been no published reports regarding the effects of these mutations on 
food intake and energy homeostasis. Based on our findings in the BEND­
deficient mice, we would predict that f..l receptor knockout mice are the most 
likely to have a phenotype relevant to the physiologic regulation of body 
weight and fat mass. 
SUMMARY AND FUTURE PROSPECTS 
Complex interactions between the nervous system and the endocrine system 
are essential for the regulation of energy homeostasis. Transgenic and 
targeted gene mutational studies have demonstrated that neuropeptides 
derived from the POMC prohormone and their cognate G-protein coupled 
receptors are key elements of communication between and within these two 
important biological systems. Transgenic models have identified POMC 
neurons in the ARC as a prominent component of the hypothalamic neural 
circuitry that modulates energy homeostasis. Moreover, melanocortin and 
opioid peptides derived from POMC may have both additive and opposing 
actions in the balance of caloric intake and expenditure. Many of the 
mutations described in this chapter give rise to multisystem physiological 
disturbances and could also involve undetected developmental alterations, 
therefore one must be circumspect in the assignment of a specific peptide or 
receptor subtype as the major determinant in a disease. As a result, newer and 
more sophisticated molecular and genetic approaches to in vivo gene 
mutations, such as conditional gene deletion and regulation, are currently 
being explored. These newer techniques will permit a more detailed 
characterization of specific endocrine-disease pathophysiology, and in 
addition, help to reveal the function of each biologically active POMC 
peptide in vivo. 
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